ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Service firm Avara buys AstraZeneca plant

by Michael McCoy
September 19, 2016 | APPEARED IN VOLUME 94, ISSUE 37

Crestor (rosuvastatin)
[+]Enlarge

One-year-old Avara Pharmaceutical Services is continuing its rapid growth with the purchase of AstraZeneca’s active pharmaceutical ingredient (API) plant in Avonmouth, England. The facility, which employs about 210 people, mainly makes the APIs in the drugs Crestor and Seroquel. Drug industry veteran Tim Tyson launched Avara in 2015 with the purchase of a Merck & Co. formulation plant in Arecibo, P.R. Earlier this year, the firm acquired a UCB API plant in Shannon, Ireland. And last month, it acquired an Astellas Pharma drug formulation and packaging plant in Norman, Okla.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment